Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Genetics

Clinical correlates of APOL1 risk genotypes

Nature Reviews Nephrology volume 11, page 504 (2015)Cite this article

Subjects

An analysis of clinical and genomic datasets from the NEPTUNE study has revealed that individuals with a high-risk APOL1 genotype present with more advanced renal disease and have less remission of proteinuria over time, independent of histologic diagnosis, compared to those with a low-risk APOL1 genotype. Sampson et al. also identified a set of transcripts that were associated with the high-risk genotype that indicate activation of innate immunity pathways and inflammation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sampson, M. G. et al. Integrative genomics identifies novel associations with APOL1 risk genotypes in black NEPTUNE subjects. J. Am. Soc. Nephrol. 10.1681/ASN.2014111131

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Clinical correlates of APOL1 risk genotypes. Nat Rev Nephrol 11, 504 (2015). https://doi.org/10.1038/nrneph.2015.123

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneph.2015.123

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing